Freedox Future In Head Injury Looks Uncertain
Pharmacia & Upjohn has decided not to pursue a head injury indication for its lazaroid drug Freedox (tirilazad mesylate) following disappointing results in two Phase III studies. However, the firm says it remains committed to finding new indications for the drug (Freedox is already approved in 11 countries for subarrachnoid hemorrhage).
The two studies, conducted in North America and Europe/Australia, did not show a consistent treatment effect for Freedox but confirmed the safety of the drug at the doses tested. P&U executive Goran Ando said that they might consider further trials of Freedox in head injury, if ongoing trials in subarrachnoid hemorrhage and ischemic stroke are positive.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze